Stocks · News reference
Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease
Nexalin Technology published a new peer-reviewed study in the Journal of Alzheimer's Disease demonstrating that its 15 mA Deep Intracranial Frequency Stimulation (DIFS™) significantly improves sleep quality in patients with mild Alzheimer's disease.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nexalin Technology Says It Regained Compliance With Nasdaq Minimum Bid Price Rule; Must Meet $2.5M Stockholders' Equity Requirement By January 4, 2027
Dow Jumps Over 300 Points; US Economy Adds 29,000 Jobs In September
U.S. stocks climbed Friday, led by Nasdaq; September jobs missed forecasts, unemployment rose, oil fell, and speculative shares surged.
Why Synaptics Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Synaptics surged 14.5% after amending its $123/share cash buyout by onsemi; AMOD led gainers, while WCT fell 20.3% premarket.
8-K filing — Nexalin Technology, Inc. (NXL)
Filed: 2026-10-01 AccNo: 0001829126-26-010686 Size: 191 KB Item 8.01: Other Events
Nasdaq Gains 100 Points; ISM manufacturing PMI Slips In September
U.S. stocks edged higher Thursday; Nasdaq rose 0.37%, energy led gains, Accenture surged 18%, and Corteva plunged 84%.